Equities analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to post earnings per share (EPS) of ($0.62) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Stemline Therapeutics’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.61). Stemline Therapeutics posted earnings of ($0.66) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The company is scheduled to report its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Stemline Therapeutics will report full-year earnings of ($2.72) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.52). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.91) per share, with EPS estimates ranging from ($2.57) to $1.54. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 101.93% and a negative net margin of 4,689.63%.
Several equities analysts recently issued reports on the stock. ValuEngine upgraded shares of Stemline Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a report on Monday, March 19th. BidaskClub lowered shares of Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, May 10th. Finally, Wedbush upped their price objective on shares of Stemline Therapeutics from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Tuesday, May 29th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $30.00.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Consonance Capital Management LP raised its holdings in shares of Stemline Therapeutics by 2,216.9% during the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after purchasing an additional 2,248,372 shares during the period. BlackRock Inc. raised its holdings in shares of Stemline Therapeutics by 11.8% during the first quarter. BlackRock Inc. now owns 1,571,426 shares of the biopharmaceutical company’s stock valued at $24,043,000 after purchasing an additional 165,245 shares during the period. Lyon Street Capital LLC raised its holdings in shares of Stemline Therapeutics by 49.7% during the first quarter. Lyon Street Capital LLC now owns 1,241,293 shares of the biopharmaceutical company’s stock valued at $18,992,000 after purchasing an additional 412,203 shares during the period. Citadel Advisors LLC acquired a new position in shares of Stemline Therapeutics during the first quarter valued at about $8,948,000. Finally, venBio Select Advisor LLC acquired a new position in shares of Stemline Therapeutics during the first quarter valued at about $8,022,000. Hedge funds and other institutional investors own 66.91% of the company’s stock.
STML stock traded down $0.35 during mid-day trading on Monday, hitting $17.45. 52,761 shares of the company were exchanged, compared to its average volume of 275,033. The company has a market capitalization of $538.88 million and a PE ratio of -5.94. Stemline Therapeutics has a 1-year low of $7.30 and a 1-year high of $20.55.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.